EGFR, déjà 20 ans

Reference

Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years 

Vansteenkiste J,   Wauters E

Annals of Oncology, 2018; 29 :  i1–i2,

Overview of current systemic management of EGFR-mutant NSCLC 

Hsu W-H, Yang JC-H, Mok TS  H, Loong HH

Annals of Oncology, 2018; 29 :  i3–i9

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors 

Westover D,  Zugazagoitia J,   Cho BC,  Lovly CM,  Paz-Ares L

Annals of Oncology, 2018; 29 :  i10–i19.

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients 

Remon J , Steuer CE, Ramalingam SS, Felip E.

Annals of Oncology, Annals of Oncology, 2018; 29 :  i20–i27,

Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer 

Ricordel C, Friboulet L, F Facchinetti F, Soria JC

Annals of Oncology, 2018; 29 : i28–i37,

Are liquid biopsies a surrogate for tissue EGFR testing? 

Goldman JW,  Noor ZS, Remon J,  Besse B, Rosenfeld N

Annals of Oncology, 2018; 29 :   i38–i46,